Promotion of anagen, increased hair density and reduction of hair fall in a clinical setting following identification of FGF5-inhibiting compounds via a novel 2-stage process.

placebo) suffered from low sample numbers and low power (Figure S3C), but in the male subgroup, a significant difference was apparent in both treatment arms compared to placebo: 0.095% p = 0.001 and 0.5% p = 0.006.

also in 830 other papers

placebo) suffered from low sample numbers and high variance in the female placebo group (Figure S2C), but in the male subgroup, we observed a borderline significant difference compared to placebo ( p = 0.08), which was not seen in the whole cohort analysis.

also in 11,409 other papers

Although it was not a primary objective of this study, statistical analysis after separation of the cohorts into male and female participants, despite low power due to small sample size and high variance in the female placebo group, identified highly significant differences from baseline in both females and males, highlighting the utility of FGF5 inhibition in the treatment of both male and female hair loss.

also in 132,142 other papers

As stated earlier, there was a strong trend for improvement in the treated groups, but in the placebo group, there was no clear trend, with some participants decreasing in anagen ratio and some increasing, resulting in a median change of 0.

also in 5,725 other papers